The Chief Executive Officer (CEO) of the FDA, Hudu Mogtari, has expressed concern about the unregulated advertisement of alcohol and its deleterious effects on children and the youth in Ghana.


Mr Mogtari said FDA was mandated by the Section 114 of the Public Health Act 2012, (Act 851) to control the advertisements of regulated products, including herbal medicines and food supplements, cosmetics, household chemical substances and medical devices, to ensure that accurate information was conveyed to the public about the products.


FDA,  he said,  was, therefore, resolved to ensuring that the health of the citizens was not compromised through the food and drugs they consumed and called on the media to ensure that the adverts broadcast and published in their media were approved by the Foods and Drugs Authority (FDA) as required by law.


In his remarks, Thomas Amedzro, Head of Drug Enforcement Department, FDA, explained that the decision to regulate the advertisement of drugs and food products in the media, as required by the Public Health law, was in the interest of public health and safety and not meant to destroy the business of any individual or group of persons in the country.


For his part, an Executive Member of the GIBA, George Fausta Baffoe, cautioned FDA “to hasten slowly” in enforcing Section 114 of the Public Health Act.


Section 113 of Act 851, which deals with the deception of consumers, states: 113.

(1) A person commits an offence if that person labels, packages, sells or advertises a drug, a herbal medicinal product, cosmetic, medical device or household chemical substance

(a) in contravention of Regulations or Guidelines made under this Part, or
(b) in a manner, that is false, misleading or deceptive or misbranded as regards its character, constitution, value, potency, quality, composition, merits or safety.

(2) For the purposes of subsection (1), a drug or herbal medicinal product is misbranded
(a) if it is so coloured, coated, powdered or polished in a manner that changes the product or if it is made to appear to be of a better or greater therapeutic value than it really is, or
(b) if it is not labelled in the prescribed manner, or
(c) if its label or container or anything accompanying the drug or herbal medicinal product bears a statement, design or device which makes a false claim for the drug or herbal medicinal product, or which is false or misleading.

Section 114 (1) of Act 851 also states:

114. (1) A person shall not advertise a drug, a herbal medicinal product, cosmetic, medical device or household chemical substance to the general public as a treatment, preventive or cure for a disease, disorder or an abnormal physical state, unless the advertisement has been approved by the Authority.


The stakeholder forum, organized by FDA, therefore, aimed to help stakeholders better appreciate the provisions of Act 851 and the FDA guidelines on the advertisement of regulated products.


The meeting also provided the platform for stakeholders to further understand the work of FDA and to foster collaboration in working to ensure that accurate information was relayed to the public about products on sale and discourage deception.


Present at the meeting were representatives of advertising agencies, media regulatory bodies such as the National Media Commission (NMC), Ghana Journalists Association (GJA), Advertising Association of Ghana (AAG), the Ghana Independent Broadcasters Association (GIBA) as well as producers and marketers of regulated products in the Greater Accra Region.


Source: ISD (G.D. Zaney)

Created: 11 September 2015
Hits: 5704